Phase 3 Readout~month

Phase 3 Topline: A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of

Indication
Breast Cancer

Other upcoming events for GLSI

Patent ExpiryPatent/Exclusivity Expiry: DUEXIS
Patent ExpiryPatent/Exclusivity Expiry: ADVIL ALLERGY SINUS
Patent ExpiryPatent/Exclusivity Expiry: DYLOJECT
Patent ExpiryPatent/Exclusivity Expiry: ZIPSOR
Patent ExpiryPatent/Exclusivity Expiry: ZORVOLEX

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of — GLSI Phase 3 Readout | BioSniper